Drug Profile
Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech
Alternative Names: Pegberon; Y-shaped pegylated interferon alfa-2b; YPEG-rhIFNα-2b - Xiamen Amoytop Biotech; Ypeginterferon alfa-2b - Xiamen Amoytop Biotech; Ypeginterferon alpha-2b - Xiamen Amoytop BiotechLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Xiamen Amoytop Biotech
- Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
- Phase III Hepatitis B
Most Recent Events
- 07 Dec 2023 Xiamen Amoytop Biotech Co completes a phase III trial in Hepatitis B (Combination therapy, Treatment-experienced, Treatment-naive) in China (SC) (NCT04846491)
- 13 Nov 2020 Efficacy data from a phase III trial in Hepatitis B presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2020)
- 27 Aug 2020 Interim adverse events data from a phase III ANCHOR trial in Hepatitis-B presented at the The International Liver Congress 2020 (ILC-2020)